APH 0812

Drug Profile

APH 0812

Alternative Names: APH-0812; Bryostatin-1/histone deacetylase inhibitors - Aphios

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aphios Corporation
  • Developer Aphios Corporation; Foundation for Biomedical Research Hospital Universitario Ramon y Cajal; VivaCell Biotechnology Espana
  • Class
  • Mechanism of Action Histone deacetylase inhibitors; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase I/II HIV infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in USA
  • 22 Feb 2016 Efficacy and adverse events data from the phase I BRYOLAT trial released by Aphios
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top